Atheroscleroses, Intracranial

2

Review clinical trials related to Atheroscleroses, Intracranial. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Plaque Characteristics Predict Recurrent Stroke in MCA Stroke Patients

The epidemiology of TOAST classification in Asian patients seems to differ due to the higher rates of large-artery atherosclerosis. The complex pathology of atherosclerosis could lead to recurrent stroke, including shear stress on the endothelium, disturbance of the flow, occlusion at the origin of the perforating artery, and other complications (plaque inflammation, plaque hemorrhage, plaque rupture) that could lead to stroke and recurrent stroke. Therefore, The exact determination of the etiology of stroke due to atherosclerosis is the most critical factor for treatment and prognostic. On the other hand, HR-MRI could be a useful imaging modality to evaluate the characteristics of plaque in stroke patients due to atherosclerosis stenosis, which will help us find out the etiology of stroke. Previous studies have demonstrated its prognosis value in predicting recurrent stroke in the same vascular territory. The investigators hypothesize that with an appropriate evaluation, HR-MRI could help to predict recurrent stroke in the same vascular territory in patients with high-risk plaque characteristics on HR-MRI. These findings could contribute to individual treatment according to etiology. The investigators intend to conduct a study to determine the correlation between plaque characteristics and recurrent stroke in the same vascular territory in ischemic stroke patients due to middle cerebral artery stenosis.

Participants needed: 75
Trial details
Age: 45-100Biological sex: AllType: ObservationalSponsor: University Medical Center Ho Chi Minh City (UMC)Updated: Aug 6, 2026Locations: 1
Eligibility criteria

Patients who had a first-time ischemic stroke due to MCA atherosclerosis stenosi... [+2]

Patients also have stenosis of the carotid artery (more than 50%) or occulsion o... [+5]

Status: Not yet recruiting

Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis

IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.

Participants needed: 486
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Zhujiang HospitalUpdated: Jul 28, 2025
Eligibility criteria

Male or non-pregnant women with acute stroke symptoms aged over 18 years. [+4]

Thrombolytic therapy or thrombectomy within 24 hours prior to enrollment. [+24]